2026 Agenda
Welcome Day
Thursday, 2/26/26
Poster Session & Welcome Reception
6:00 PM - 8:00 PM
Curb Conservatory & Hall of Fame Rotunda
Day One
Friday, 2/27/26
Fellows and Faculty Breakfast
7:30 AM - 8:20 AM
Event Hall
Hosted by chairs:
Joanna Rhodes, MD, MSCE (Rutgers Cancer Institute of New Jersey)
Jesús Berdeja, MD (Greco-Hainsworth Tennessee Oncology Centers for Research)
Andrew Kuykendall, MD (Moffitt Cancer Center)
Sponsored by
Benign Hematology
Pre-Malignant Hematologic Disorders: What Do Community Providers Need to Know?
1L Standard of Care Across Lymphoid Malignancies: What's New in 2026?
1L Standard of Care Across Myeloid Malignancies: What's New in 2026?
Considerations in Treating Patients with High-Risk Hematologic Malignancies
Challenging Clinical Scenarios in the Community
Benign Hematology
Session Chair: Jennifer Green, MD (Tennessee Oncology)
CMA Theater
8:50 AM
Evolving Diagnostics in Iron Deficiency Anemia
Angela Weyand, MD (University of Michigan)
8:58 AM
The Bleeding Patient Consult
Michelle Chi, MD (Vanderbilt Health)
9:06 AM
New Developments in Sickle Cell Disease
Scott Peslak, MD, PhD (University of Pennsylvania)
9:14 AM
TTP/HUS
Spero Cataland, MD (The Ohio State University)
9:22 AM
Managing Thrombosis
Adam Cuker, MD, MS (University of Pennsylvania)
9:30 AM
Panel Discussion + Q&A
Pre-Malignant Hematologic Disorders: What Do Community Providers Need to Know?
Session Chair: Michael Byrne, DO, FACP (Greco-Hainsworth Tennessee Oncology Centers for Research)
CMA Theater
9:48 AM
MGUS/ SMM
Suzanne Lentzsch, MD, PhD (Columbia University Medical Center)
9:56 AM
CHIP/CCUS
Zhuoer Xie, MD, MS (Moffitt Cancer Center)
10:04 AM
MBL: Implications on Infectious Risk
Sameer Parikh, MBBS (Mayo Clinic)
10:12 AM
Panel Discussion + Q&A
Networking Break
10:30 AM - 11:00 AM
Grand Foyer
1L Standard of Care Across Lymphoid Malignancies: What's New in 2026?
Session Chair: Jason Chandler, MD (West Cancer Center & Research Institute)
CMA Theater
11:00 AM
Debate: Single Agent Monotherapy Vs Fixed Duration Combos in Frontline CLL
Adam Kittai, MD (Mount Sinai Health System)
Callie Coombs, MD (University of California Irvine)
11:20 AM
Multiple Myeloma
Amrita Krishnan, MD, FACP (City of Hope)
11:28 AM
Diffuse Large B-Cell Lymphoma
Ryan Lynch, MD (Fred Hutch Cancer Center)
11:36 AM
Hodgkin’s Lymphoma
Boyu Hu, MD (Huntsman Cancer Institute)
11:44 AM
Indolent Lymphomas
Elizabeth Brém, MD (University of California Irvine)
11:52 AM
Panel Discussion + Q&A
Lunch - Interpreting Genetic Sequencing
12:25 PM - 1:25 PM
Event Hall
Moderator:
Jonathan Abbas, MD (Tennessee Oncology)
Sponsored by
1L Standard of Care Across Myeloid Malignancies: What's New in 2026?
Session Chair: Ruben Mesa, MD, FACP (Atrium Health Levine Cancer Institute)
CMA Theater
1:40 PM
Myelofibrosis
John Mascarenhas, MD (Mount Sinai Health System)
1:48 PM
Chronic Myeloid Leukemia
Srinivas Tantravahi, MBBS, MRCP (Huntsman Cancer Institute)
1:56 PM
Myelodysplastic Syndromes
Anthony Hunter, MD (Winship Cancer Institute of Emory University)
2:04 PM
Myeloproliferative Neoplasms
Gabriela Hobbs, MD (Massachusetts General Hospital)
2:12 PM
Panel Discussion + Q&A
Considerations in Treating Patients with High-Risk Hematologic Malignancies
Session Chair: Joshua Richter, MD, FACP (Mount Sinai Health System)
CMA Theater
2:32 PM
Defining High-Risk Disease in Lymphoid Malignancies
Jeremy Abramson, MD (Harvard Medical School)
2:40 PM
High-Risk Multiple Myeloma: Time For a Paradigm Change?
Natalie Callander, MD (University of Wisconsin)
2:48 PM
TP53-Mutated AML and MDS
David Sallman, MD (Moffitt Cancer Center)
2:56 PM
Panel Discussion + Q&A
Networking Break
3:15 PM - 3:45 PM
Grand Foyer
Challenging Clinical Scenarios in the Community
Session Chair: Alexander Perl, MD (University of Pennsylvania)
CMA Theater
3:45 PM
Renal Insufficiency in Multiple Myeloma
Rahul Banerjee, MD, FACP (Fred Hutch Cancer Center)
3:53 PM
How To Tackle Curative Intent in Lymphoma Patients With Cardiac Comorbidities
4:01 PM
MDS/MPN Overlap Syndromes
Eric Padron, MD (Moffitt Cancer Center)
4:09 PM
Debate: Intensive Vs Less Intensive Induction For The Treatment of Older, But Fit, Patients With Newly Diagnosed AML
Dan Pollyea, MD, MS (University of Colorado School of Medicine)
Jeffrey Lancet, MD (Moffitt Cancer Center)
4:29 PM
Panel Discussion + Q&A
Day Two
Saturday, 2/28/26
Breakfast - Women Leaders in Hematology
7:30 AM - 8:20 AM
Event Hall
Moderator:
Joanna Rhodes, MD, MSCE (Rutgers Cancer Institute of New Jersey)
Sponsored by
MRD Across Hematologic Malignancies
Non-Cellular Approaches in Treating Relapsed/Refractory Hematologic Malignancies
Cellular and T-cell Redirecting Therapies in Hematologic Malignancies
Amuse-Bouche: Myeloma at the Movies
Advancing Community Care
The Evolving Treatment Landscape Across Hematologic Malignancies: What's on the Horizon?
MRD Across Hematologic Malignancies
Session Chair: Christopher Benton, MD (Rocky Mountain Cancer Centers)
CMA Theater
8:45 AM
MRD in AML: Who, What, When, and How?
Rory Shallis, MD (Moffitt Cancer Center)
8:53 AM
Defining The Value of uMRD in CLL
Chaitra Ujjani, MD (Fred Hutch Cancer Center)
9:01 AM
MRD in Multiple Myeloma: How, When and Why?
Noopur Raje, MD (Massachusetts General Hospital)
9:09 AM
ctDNA in Lymphoma
Sairah Ahmed, MD (MD Anderson Cancer Center)
9:17 AM
Debate: Is Monotherapy Maintenance Until Progression The Optimal Approach To Maintenance Therapy in Multiple Myeloma in The Era of Quadruplet Induction?
Peter Voorhees, MD (Atrium Health Levine Cancer Institute)
Faith Davies, MD (NYU Langone Health)
9:37 AM
Panel Discussion + Q&A
Non-Cellular Approaches in Treating Relapsed/Refractory Hematologic Malignancies
Session Chair: Katie Largent, DMSc, PA-C, CPAAPA (Tennessee Oncology)
CMA Theater
9:55 AM
Multiple Myeloma
Caitlin Costello, MD (University of California San Diego)
10:03 AM
CLL
Jacqueline Barrientos, MD, MS (Mount Sinai Health System)
10:11 AM
Indolent Lymphomas
Krish Patel, MD (Sarah Cannon Research Institute)
10:19 AM
Acute Myeloid Leukemia
Rami Komrokji, MD (Moffitt Cancer Center)
10:27 AM
Panel Discussion + Q&A
Networking Break
10:45 AM - 11:15 AM
Grand Foyer
Cellular and T-Cell Redirecting Therapies in Hematologic Malignancies
Session Chair: Yi Lin, MD, PhD (Mayo Clinic)
CMA Theater
11:15 AM
CAR-T in Multiple Myeloma
Krina Patel, MD (MD Anderson Cancer Center)
11:23 AM
CAR-T in Non-Hodgkin’s Lymphoma
11:31 AM
Bispecifics in Multiple Myeloma
Susan Bal, MD (University of Alabama Birmingham)
11:39 AM
Bispecifics in Lymphomas
Tycel Phillips, MD (City of Hope)
11:47 AM
Managing Acute Toxicities with Cellular and T-Cell Redirecting Therapies
Babis Andreadis, MD, MS (University of California San Francisco)
11:55 AM
Panel Discussion + Q&A
Amuse-Bouche: Myeloma at the Movies
12:15 AM
Remember the Future
Saad Usmani, MD, MBA, FACP, FASCO (Memorial Sloan Kettering Cancer Center)
Lunch - Optimal Sequencing in RRMM
12:40 PM - 1:40 PM
Event Hall
Moderator:
Peter Voorhees, MD (Atrium Health Levine Cancer Institute)
Sponsored by Johnson & Johnson and Kite
Advancing Community Care
Session Chair: Jonathan Abbas, MD (Tennessee Oncology)
CMA Theater
1:55 PM
Utilizing Remote Consultation To Optimize Patient Care in The Community Setting
Jennifer Green, MD (Tennessee Oncology)
2:03 PM
Utilizing Frailty Indexes
Reena Jayani-Kosarzycki, MD, MSCI (Vanderbilt Health)
2:11 PM
Bringing Bispecifics to the Community
Tara Graff, DO, MS (Mission Cancer + Blood)
2:19 PM
Managing Long-Term Toxicities With Cellular and T-Cell Redirecting Therapies
Adam Cohen, MD (University of Pennsylvania)
2:27 PM
Panel Discussion +Q&A
Networking Break
2:45 PM - 3:15 PM
Grand Foyer
The Evolving Treatment Landscape Across Hematologic Malignancies: What's On The Horizon?
Session Chair: Vernon Wu, MD (New York Cancer and Blood Specialists)
CMA Theater
3:15 PM
Multiple Myeloma
Ajay Nooka, MD, MPH (Winship Cancer Institute of Emory University)
3:23 PM
CLL
Deborah Stephens, DO (University of North Carolina School of Medicine)
3:31 PM
Non-Hodgkin’s Lymphoma
3:39 PM
AML+MDS
Uma Borate, MBBS (The Ohio State University)
3:47 PM
MPNs +SM+CML
Kristen Pettit, MD (University of Michigan)
3:55 PM
Q&A
Keynote Speaker (Non-CE)
David Fajgenbaum, MD, MBA, MSc
Associate Professor of Medicine at the University of Pennsylvania and Co-Founder and President of Everycure
From Chasing My Cure to Every Cure: Utilizing Novel Approaches to Uncover New Uses for Existing Medicines
4:15 PM - 5:00 PM
CMA Theatre
Farewell Reception
5:00 PM - 6:00 PM
Grand Foyer
*Agenda is subject to change.
Experience Nashville, TN